Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Olivia Fletcher is active.

Publication


Featured researches published by Olivia Fletcher.


The Lancet | 2004

The cervical cancer epidemic that screening has prevented in the UK

Julian Peto; Clare Gilham; Olivia Fletcher; Fiona E. Matthews

BACKGROUND Recent reports suggest that the reduction in mortality achieved by the UK national cervical screening programme is too small to justify its financial and psychosocial costs, except perhaps in a few high-risk women. METHODS We analysed trends in mortality before 1988, when the British national screening programme was launched, to estimate what future trends in cervical cancer mortality would have been without any screening. FINDINGS Cervical cancer mortality in England and Wales in women younger than 35 years rose three-fold from 1967 to 1987. By 1988, incidence in this age-range was among the highest in the world despite substantial opportunistic screening. Since national screening was started in 1988, this rising trend has been reversed. INTERPRETATION Cervical screening has prevented an epidemic that would have killed about one in 65 of all British women born since 1950 and culminated in about 6000 deaths per year in this country. However, these estimates are subject to substantial uncertainty, particularly in relation to the effects of oral contraceptives and changes in sexual behaviour. 80% or more of these deaths (up to 5000 deaths per year) are likely to be prevented by screening, which means that about 100000 (one in 80) of the 8 million British women born between 1951 and 1970 will be saved from premature death by the cervical screening programme at a cost per life saved of about pound 36000. The birth cohort trends also provide strong evidence that the death rate throughout life is substantially lower in women who were first screened when they were younger.


Nature Genetics | 2007

A common coding variant in CASP8 is associated with breast cancer risk

Angela Cox; Alison M. Dunning; Montserrat Garcia-Closas; Sabapathy P. Balasubramanian; Malcolm Reed; Karen A. Pooley; Serena Scollen; Caroline Baynes; Bruce A.J. Ponder; Stephen J. Chanock; Jolanta Lissowska; Louise A. Brinton; Beata Peplonska; Melissa C. Southey; John L. Hopper; Margaret McCredie; Graham G. Giles; Olivia Fletcher; Nichola Johnson; Isabel dos Santos Silva; Lorna Gibson; Stig E. Bojesen; Børge G. Nordestgaard; Christen K. Axelsson; Diana Torres; Ute Hamann; Christina Justenhoven; Hiltrud Brauch; Jenny Chang-Claude; Silke Kropp

The Breast Cancer Association Consortium (BCAC) has been established to conduct combined case-control analyses with augmented statistical power to try to confirm putative genetic associations with breast cancer. We genotyped nine SNPs for which there was some prior evidence of an association with breast cancer: CASP8 D302H (rs1045485), IGFBP3 −202 C → A (rs2854744), SOD2 V16A (rs1799725), TGFB1 L10P (rs1982073), ATM S49C (rs1800054), ADH1B 3′ UTR A → G (rs1042026), CDKN1A S31R (rs1801270), ICAM5 V301I (rs1056538) and NUMA1 A794G (rs3750913). We included data from 9–15 studies, comprising 11,391–18,290 cases and 14,753–22,670 controls. We found evidence of an association with breast cancer for CASP8 D302H (with odds ratios (OR) of 0.89 (95% confidence interval (c.i.): 0.85–0.94) and 0.74 (95% c.i.: 0.62–0.87) for heterozygotes and rare homozygotes, respectively, compared with common homozygotes; Ptrend = 1.1 × 10−7) and weaker evidence for TGFB1 L10P (OR = 1.07 (95% c.i.: 1.02–1.13) and 1.16 (95% c.i.: 1.08–1.25), respectively; Ptrend = 2.8 × 10−5). These results demonstrate that common breast cancer susceptibility alleles with small effects on risk can be identified, given sufficiently powerful studies.NOTE: In the version of this article initially published, there was an error that affected the calculations of the odds ratios, confidence intervals, between-study heterogeneity, trend test and test for association for SNP ICAM5 V301I in Table 1 (ICAM5 V301I); genotype counts in Supplementary Table 2 (ICAM5; ICR_FBCS and Kuopio studies) and minor allele frequencies, trend test and odds ratios for heterozygotes and rare homozygotes in Supplementary Table 3 (ICAM5; ICR_FBCS and Kuopio studies). The errors in Table 1 have been corrected in the PDF version of the article. The errors in supplementary information have been corrected online.


Journal of the National Cancer Institute | 2011

Novel Breast Cancer Susceptibility Locus at 9q31.2: Results of a Genome-Wide Association Study

Olivia Fletcher; Nichola Johnson; Nick Orr; Fay J. Hosking; Lorna Gibson; Kate Walker; Diana Zelenika; Ivo Gut; Simon Heath; Claire Palles; Ben Coupland; Peter Broderick; Minouk J. Schoemaker; Michael E. Jones; Jill Williamson; Sarah Chilcott-Burns; Katarzyna Tomczyk; Gemma Simpson; Kevin B. Jacobs; Stephen J. Chanock; David J. Hunter; Ian Tomlinson; Anthony J. Swerdlow; Alan Ashworth; Gillian Ross; Isabel dos Santos Silva; Mark Lathrop; Richard S. Houlston; Julian Peto

BACKGROUND Genome-wide association studies have identified several common genetic variants associated with breast cancer risk. It is likely, however, that a substantial proportion of such loci have not yet been discovered. METHODS We compared 296,114 tagging single-nucleotide polymorphisms in 1694 breast cancer case subjects (92% with two primary cancers or at least two affected first-degree relatives) and 2365 control subjects, with validation in three independent series totaling 11,880 case subjects and 12,487 control subjects. Odds ratios (ORs) and associated 95% confidence intervals (CIs) in each stage and all stages combined were calculated using unconditional logistic regression. Heterogeneity was evaluated with Cochran Q and I(2) statistics. All statistical tests were two-sided. RESULTS We identified a novel risk locus for breast cancer at 9q31.2 (rs865686: OR = 0.89, 95% CI = 0.85 to 0.92, P = 1.75 × 10(-10)). This single-nucleotide polymorphism maps to a gene desert, the nearest genes being Kruppel-like factor 4 (KLF4, 636 kb centromeric), RAD23 homolog B (RAD23B, 794 kb centromeric), and actin-like 7A (ACTL7A, 736 kb telomeric). We also identified two variants (rs3734805 and rs9383938) mapping to 6q25.1 estrogen receptor 1 (ESR1), which were associated with breast cancer in subjects of northern European ancestry (rs3734805: OR = 1.19, 95% CI = 1.11 to 1.27, P = 1.35 × 10(-7); rs9383938: OR = 1.18, 95% CI = 1.11 to 1.26, P = 1.41 × 10(-7)). A variant mapping to 10q26.13, approximately 300 kb telomeric to the established risk locus within the second intron of FGFR2, was also associated with breast cancer risk, although not at genome-wide statistical significance (rs10510102: OR = 1.12, 95% CI = 1.07 to 1.17, P = 1.58 × 10(-6)). CONCLUSIONS These findings provide further evidence on the role of genetic variation in the etiology of breast cancer. Fine mapping will be needed to identify causal variants and to determine their functional effects.


Cancer Research | 2012

Intragenic ATM Methylation in Peripheral Blood DNA as a Biomarker of Breast Cancer Risk

Kevin Brennan; Montserrat Garcia-Closas; Nick Orr; Olivia Fletcher; Michael P. Jones; Alan Ashworth; Anthony J. Swerdlow; Heather Thorne; Elio Riboli; Paolo Vineis; Miren Dorronsoro; Françoise Clavel-Chapelon; Salvatore Panico; N. Charlotte Onland-Moret; Dimitrios Trichopoulos; Rudolf Kaaks; Kay-Tee Khaw; Robert Brown; James M. Flanagan

Few studies have evaluated the association between DNA methylation in white blood cells (WBC) and the risk of breast cancer. The evaluation of WBC DNA methylation as a biomarker of cancer risk is of particular importance as peripheral blood is often available in prospective cohorts and easier to obtain than tumor or normal tissues. Here, we used prediagnostic blood samples from three studies to analyze WBC DNA methylation of two ATM intragenic loci (ATMmvp2a and ATMmvp2b) and genome-wide DNA methylation in long interspersed nuclear element-1 (LINE1) repetitive elements. Samples were from a case-control study derived from a cohort of high-risk breast cancer families (KConFab) and nested case-control studies in two prospective cohorts: Breakthrough Generations Study (BGS) and European Prospective Investigation into Cancer and Nutrition (EPIC). Bisulfite pyrosequencing was used to quantify methylation from 640 incident cases of invasive breast cancer and 741 controls. Quintile analyses for ATMmvp2a showed an increased risk of breast cancer limited to women in the highest quintile [OR, 1.89; 95% confidence interval (CI), 1.36-2.64; P = 1.64 × 10(-4)]. We found no significant differences in estimates across studies or in analyses stratified by family history or menopausal status. However, a more consistent association was observed in younger than in older women and individually significant in KConFab and BGS, but not EPIC. We observed no differences in LINE1 or ATMmvp2b methylation between cases and controls. Together, our findings indicate that WBC DNA methylation levels at ATM could be a marker of breast cancer risk and further support the pursuit of epigenome-wide association studies of peripheral blood DNA methylation.


Human Molecular Genetics | 2009

Gene-body hypermethylation of ATM in peripheral blood DNA of bilateral breast cancer patients

James M. Flanagan; Marta Munoz-Alegre; Stephen Henderson; Thomas Tang; Ping Sun; Nichola Johnson; Olivia Fletcher; Isabel dos Santos Silva; Julian Peto; Chris Boshoff; Steven A. Narod; Arturas Petronis

Bilaterality of breast cancer is an indicator of constitutional cancer susceptibility; however, the molecular causes underlying this predisposition in the majority of cases is not known. We hypothesize that epigenetic misregulation of cancer-related genes could partially account for this predisposition. We have performed methylation microarray analysis of peripheral blood DNA from 14 women with bilateral breast cancer compared with 14 unaffected matched controls throughout 17 candidate breast cancer susceptibility genes including BRCA1, BRCA2, CHEK2, ATM, ESR1, SFN, CDKN2A, TP53, GSTP1, CDH1, CDH13, HIC1, PGR, SFRP1, MLH1, RARB and HSD17B4. We show that the majority of methylation variability is associated with intragenic repetitive elements. Detailed validation of the tiled region around ATM was performed by bisulphite modification and pyrosequencing of the same samples and in a second set of peripheral blood DNA from 190 bilateral breast cancer patients compared with 190 controls. We show significant hypermethylation of one intragenic repetitive element in breast cancer cases compared with controls (P = 0.0017), with the highest quartile of methylation associated with a 3-fold increased risk of breast cancer (OR 3.20, 95% CI 1.78–5.86, P = 0.000083). Increased methylation of this locus is associated with lower steady-state ATM mRNA level and correlates with age of cancer patients but not controls, suggesting a combined age–phenotype-related association. This research demonstrates the potential for gene-body epigenetic misregulation of ATM and other cancer-related genes in peripheral blood DNA that may be useful as a novel marker to estimate breast cancer risk. Accession numbers: The microarray data and associated .BED and .WIG files can be accessed through Gene Expression Omnibus accession number: GSE14603.


Journal of the National Cancer Institute | 2009

Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042

Roger L. Milne; Javier Benitez; Heli Nevanlinna; Tuomas Heikkinen; Kristiina Aittomäki; Carl Blomqvist; José Ignacio Arias; M. Pilar Zamora; Barbara Burwinkel; Claus R. Bartram; Alfons Meindl; Rita K. Schmutzler; Angela Cox; Ian W. Brock; Graeme Elliott; Malcolm Reed; Melissa C. Southey; Letitia Smith; Amanda B. Spurdle; John L. Hopper; Fergus J. Couch; Janet E. Olson; Xianshu Wang; Zachary S. Fredericksen; Peter Schürmann; Michael Bremer; Peter Hillemanns; Thilo Dörk; Peter Devilee; Christie J. van Asperen

BACKGROUND A recent genome-wide association study identified single-nucleotide polymorphism (SNP) 2q35-rs13387042 as a marker of susceptibility to estrogen receptor (ER)-positive breast cancer. We attempted to confirm this association using the Breast Cancer Association Consortium. METHODS 2q35-rs13387042 SNP was genotyped for 31 510 women with invasive breast cancer, 1101 women with ductal carcinoma in situ, and 35 969 female control subjects from 25 studies. Odds ratios (ORs) were estimated by logistic regression, adjusted for study. Heterogeneity in odds ratios by each of age, ethnicity, and study was assessed by fitting interaction terms. Heterogeneity by each of invasiveness, family history, bilaterality, and hormone receptor status was assessed by subclassifying case patients and applying polytomous logistic regression. All statistical tests were two-sided. RESULTS We found strong evidence of association between rs13387042 and breast cancer in white women of European origin (per-allele OR = 1.12, 95% confidence interval [CI] = 1.09 to 1.15; P(trend) = 1.0 x 10(-19)). The odds ratio was lower than that previously reported (P = .02) and did not vary by age or ethnicity (all P > or = .2). However, it was higher when the analysis was restricted to case patients who were selected for a strong family history (P = .02). An association was observed for both ER-positive (OR = 1.14, 95% CI = 1.10 to 1.17; P = 10(-15)) and ER-negative disease (OR = 1.10, 95% CI = 1.04 to 1.15; P = .0003) and both progesterone receptor (PR)-positive (OR = 1.15, 95% CI = 1.11 to 1.19; P = 5 x 10(-14)) and PR-negative disease (OR = 1.10, 95% CI = 1.06 to 1.15; P = .00002). CONCLUSION The rs13387042 is associated with both ER-positive and ER-negative breast cancer in European women.


Breast Cancer Research | 2010

Assessing interactions between the associations of common genetic susceptibility variants, reproductive history and body mass index with breast cancer risk in the breast cancer association consortium: a combined case-control study.

Roger L. Milne; Mia M. Gaudet; Amanda B. Spurdle; Peter A. Fasching; Fergus J. Couch; Javier Benitez; Jose Ignacio Arias Perez; M. Pilar Zamora; Núria Malats; Isabel dos Santos Silva; Lorna Gibson; Olivia Fletcher; Nichola Johnson; Hoda Anton-Culver; Argyrios Ziogas; Jonine D. Figueroa; Louise A. Brinton; Mark E. Sherman; Jolanta Lissowska; John L. Hopper; Gillian S. Dite; Carmel Apicella; Melissa C. Southey; Alice J. Sigurdson; Martha S. Linet; Sara J. Schonfeld; D. Michal Freedman; Arto Mannermaa; Veli-Matti Kosma; Vesa Kataja

IntroductionSeveral common breast cancer genetic susceptibility variants have recently been identified. We aimed to determine how these variants combine with a subset of other known risk factors to influence breast cancer risk in white women of European ancestry using case-control studies participating in the Breast Cancer Association Consortium.MethodsWe evaluated two-way interactions between each of age at menarche, ever having had a live birth, number of live births, age at first birth and body mass index (BMI) and each of 12 single nucleotide polymorphisms (SNPs) (10q26-rs2981582 (FGFR2), 8q24-rs13281615, 11p15-rs3817198 (LSP1), 5q11-rs889312 (MAP3K1), 16q12-rs3803662 (TOX3), 2q35-rs13387042, 5p12-rs10941679 (MRPS30), 17q23-rs6504950 (COX11), 3p24-rs4973768 (SLC4A7), CASP8-rs17468277, TGFB1-rs1982073 and ESR1-rs3020314). Interactions were tested for by fitting logistic regression models including per-allele and linear trend main effects for SNPs and risk factors, respectively, and single-parameter interaction terms for linear departure from independent multiplicative effects.ResultsThese analyses were applied to data for up to 26,349 invasive breast cancer cases and up to 32,208 controls from 21 case-control studies. No statistical evidence of interaction was observed beyond that expected by chance. Analyses were repeated using data from 11 population-based studies, and results were very similar.ConclusionsThe relative risks for breast cancer associated with the common susceptibility variants identified to date do not appear to vary across women with different reproductive histories or body mass index (BMI). The assumption of multiplicative combined effects for these established genetic and other risk factors in risk prediction models appears justified.


The Lancet | 2005

Interaction between CHEK2*1100delC and other low-penetrance breast-cancer susceptibility genes: a familial study

Nichola Johnson; Olivia Fletcher; Cristina Naceur-Lombardelli; Isabel dos Santos Silva; Alan Ashworth; Julian Peto

BACKGROUND The allele CHEK2*1100delC doubles the risk of breast cancer in unselected women, but could confer a greater risk in women with a family history of the disease, particularly of bilateral breast cancer. Our aim was to measure the risk of breast cancer in relatives of women with bilateral breast cancer who were carriers of this allele. METHODS A population-based series of 469 bilateral breast cancer cases ascertained through English cancer registries were genotyped for CHEK2*1100delC. Standardised incidence ratios (SIRs) and cumulative risks were calculated for breast cancer, prostate cancer, and all other cancers in the first-degree relatives of carriers and non-carriers. FINDINGS The relatives of bilateral cases who were wild-type for CHEK2 had three times the population risk of female breast cancer (145 cases: SIR 3.48 (95% CI 2.96-4.09), twice the risk of prostate cancer (34 cases: SIR 2.41, 1.67-3.36) and a large excess of male breast cancer (five cases: SIR 15.06, 4.92-35.36). Relatives of those who were carriers of CHEK2*1100delC had a substantially higher risk of breast cancer (eight cases: SIR 12.11, 5.23-23.88) and possibly prostate cancer (two cases: SIR 9.87, 1.20-35.67). INTERPRETATION These data suggest a multiplicative interaction between CHEK2*1100delC and other unknown susceptibility genes. In women with a family history of bilateral disease, CHEK2*1100delC confers a high lifetime risk and might be useful for predictive testing. Bilateral breast cancer cases and their families are likely to provide an efficient basis for identification of additional low-penetrance breast-cancer genes.


Nature Communications | 2015

Capture Hi-C identifies the chromatin interactome of colorectal cancer risk loci

Roland Jäger; Gabriele Migliorini; Marc Henrion; Radhika Kandaswamy; Helen E. Speedy; Andreas Heindl; Nicola Whiffin; Maria J. Carnicer; Laura Broome; Nicola Dryden; Takashi Nagano; Stefan Schoenfelder; Martin Enge; Yinyin Yuan; Jussi Taipale; Peter Fraser; Olivia Fletcher; Richard S. Houlston

Multiple regulatory elements distant from their targets on the linear genome can influence the expression of a single gene through chromatin looping. Chromosome conformation capture implemented in Hi-C allows for genome-wide agnostic characterization of chromatin contacts. However, detection of functional enhancer–promoter interactions is precluded by its effective resolution that is determined by both restriction fragmentation and sensitivity of the experiment. Here we develop a capture Hi-C (cHi-C) approach to allow an agnostic characterization of these physical interactions on a genome-wide scale. Single-nucleotide polymorphisms associated with complex diseases often reside within regulatory elements and exert effects through long-range regulation of gene expression. Applying this cHi-C approach to 14 colorectal cancer risk loci allows us to identify key long-range chromatin interactions in cis and trans involving these loci.


Cancer Research | 2011

Common Breast Cancer Susceptibility Loci Are Associated with Triple-Negative Breast Cancer

Kristen N. Stevens; Celine M. Vachon; Adam Lee; Susan L. Slager; Timothy G. Lesnick; Curtis Olswold; Peter A. Fasching; Penelope Miron; Diana Eccles; Jane Carpenter; Andrew K. Godwin; Christine B. Ambrosone; Robert Winqvist; Hiltrud Brauch; Marjanka K. Schmidt; Angela Cox; Simon S. Cross; Elinor Sawyer; Arndt Hartmann; Matthias W. Beckmann; Rud̈iger Schulz-Wendtland; Arif B. Ekici; William Tapper; Susan M. Gerty; Lorraine Durcan; Nikki Graham; Rebecca Hein; Stephan Nickels; Dieter Flesch-Janys; Judith Heinz

Triple-negative breast cancers are an aggressive subtype of breast cancer with poor survival, but there remains little known about the etiologic factors that promote its initiation and development. Commonly inherited breast cancer risk factors identified through genome-wide association studies display heterogeneity of effect among breast cancer subtypes as defined by the status of estrogen and progesterone receptors. In the Triple Negative Breast Cancer Consortium (TNBCC), 22 common breast cancer susceptibility variants were investigated in 2,980 Caucasian women with triple-negative breast cancer and 4,978 healthy controls. We identified six single-nucleotide polymorphisms, including rs2046210 (ESR1), rs12662670 (ESR1), rs3803662 (TOX3), rs999737 (RAD51L1), rs8170 (19p13.1), and rs8100241 (19p13.1), significantly associated with the risk of triple-negative breast cancer. Together, our results provide convincing evidence of genetic susceptibility for triple-negative breast cancer.

Collaboration


Dive into the Olivia Fletcher's collaboration.

Top Co-Authors

Avatar

Nichola Johnson

Institute of Cancer Research

View shared research outputs
Top Co-Authors

Avatar

Julian Peto

Institute of Cancer Research

View shared research outputs
Top Co-Authors

Avatar

Nick Orr

Institute of Cancer Research

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Richard S. Houlston

Institute of Cancer Research

View shared research outputs
Top Co-Authors

Avatar

Anthony J. Swerdlow

Institute of Cancer Research

View shared research outputs
Top Co-Authors

Avatar

Katarzyna Tomczyk

Institute of Cancer Research

View shared research outputs
Top Co-Authors

Avatar

Claire Palles

Wellcome Trust Centre for Human Genetics

View shared research outputs
Researchain Logo
Decentralizing Knowledge